Cover Image
市場調查報告書

胃抑制多胜肽受體 (GIPR):開發平台分析

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 358351
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
胃抑制多胜肽受體 (GIPR):開發平台分析 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 44 Pages
簡介

本報告提供胃抑制多胜肽受體 (GIPR) 的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃相關資訊,以及最近的新聞和發表等訊息。

簡介

  • 調查範圍

胃抑制多胜肽受體 (GIPR) 概要

治療藥的開發

  • 胃抑制多胜肽受體 (GIPR):開發中的產品 - 各開發階段
  • 胃抑制多胜肽受體 (GIPR):開發中的產品 - 各治療範圍
  • 胃抑制多胜肽受體 (GIPR) 開發中的產品 - 各適應症

胃抑制多胜肽受體 (GIPR):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

胃抑制多胜肽受體 (GIPR):企業開發中的產品

胃抑制多胜肽受體 (GIPR):大學/機關開發中的產品

胃抑制多胜肽受體 (GIPR):治療藥的評估

單劑療法/聯合治療產品的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

胃抑制多胜肽受體 (GIPR) 的治療藥開發企業

  • Alchemia Limited
  • AstraZeneca Plc
  • Carmot Therapeutics, Inc.
  • Diabetica Limited
  • Longevity Biotech, Inc
  • Novo Nordisk A/S
  • Sanofi
  • Zealand Pharma A/S

胃抑制多胜肽受體 (GIPR) 的藥物簡介

胃抑制多胜肽受體 (GIPR):暫停中的計劃

胃抑制多胜肽受體 (GIPR):開發中止的產品

胃抑制多胜肽受體 (GIPR):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1008TDB

Summary:

According to the recently published report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017'; Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.

The report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH) and Parkinson's Disease.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
    • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
    • Antag Therapeutics ApS
    • Carmot Therapeutics Inc
    • Eli Lilly and Company
    • Hanmi Pharmaceuticals Co Ltd
    • Longevity Biotech Inc
    • Novo Nordisk A/S
    • Sanofi
    • Zealand Pharma AS
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
    • DAJC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-15211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBT-6030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3298176 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNC-92041706 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Antagonize GIPR for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-438335 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GLP1 and GIP Receptors for Non Alcoholic Steatohepatitis, Obesity and Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide 1 for Type 2 Diabetes and Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize GIPR for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPDI-70 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPI-98 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting
      • Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scientific Sessions
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Antag Therapeutics ApS, H2 2017
  • Pipeline by Carmot Therapeutics Inc, H2 2017
  • Pipeline by Eli Lilly and Company, H2 2017
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Pipeline by Longevity Biotech Inc, H2 2017
  • Pipeline by Novo Nordisk A/S, H2 2017
  • Pipeline by Sanofi, H2 2017
  • Pipeline by Zealand Pharma AS, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top